• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阻碍发现1型糖尿病基于干预的治疗方法的因素。

Factors impeding the discovery of an intervention-based treatment for type 1 diabetes.

作者信息

von Herrath M G, Korsgren O, Atkinson M A

机构信息

Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA.

Novo Nordisk Diabetes Research and Development Center, Seattle, WA, USA.

出版信息

Clin Exp Immunol. 2016 Jan;183(1):1-7. doi: 10.1111/cei.12656. Epub 2015 Jul 24.

DOI:10.1111/cei.12656
PMID:25989477
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4687509/
Abstract

Type 1 diabetes (T1D) is one of the most common and severe chronic diseases affecting both children and adults. The aetiology of the disease remains unknown, and thus far no 'true' cure for those affected is available. Indeed, exogenous insulin replacement therapy to manage glucose metabolism to the best degree possible remains the current standard of care. However, despite a recent array of truly impressive improvements designed to enhance disease management (e.g. insulin analogues, continuous glucose monitoring, insulin pumps), it is still difficult for the vast majority of patients to reach recommended target HbA1C levels (< 7.0%). As a result of suboptimal disease management, far too many patients with T1D have an increased risk for disease-associated complications such as nephropathy, neuropathy and retinopathy, as well as hypoglycaemia. New treatment modalities are therefore needed urgently to bring a 'true' cure (disease prevention/disease reversal) to patients with T1D. Here we consider issues that collectively pose a major stumbling block in T1D research with respect to identifying a means to prevent and/or cure the disease. We begin this Perspective by discussing new insights emanating from studies of the pancreas in human T1D; findings which may, at least in part, explain why previous interventions seeking disease prevention/reversal have yielded insufficient benefit. We then turn to suggestions that could optimise the outcome of future clinical trials. Finally, we direct attention to recommendations for the global T1D research community; messages we deem to have the potential to improve our chances of finding the elusive T1D 'cure'.

摘要

1型糖尿病(T1D)是影响儿童和成人的最常见、最严重的慢性病之一。该疾病的病因尚不清楚,迄今为止,还没有针对患者的“真正”治愈方法。事实上,通过外源性胰岛素替代疗法尽可能最佳地管理葡萄糖代谢仍然是当前的标准治疗方法。然而,尽管最近有一系列旨在加强疾病管理的真正令人印象深刻的改进措施(如胰岛素类似物、持续葡萄糖监测、胰岛素泵),但绝大多数患者仍难以达到推荐的糖化血红蛋白(HbA1C)目标水平(<7.0%)。由于疾病管理欠佳,太多T1D患者发生肾病、神经病变和视网膜病变等与疾病相关并发症以及低血糖的风险增加。因此,迫切需要新的治疗方法,为T1D患者带来“真正”的治愈方法(疾病预防/疾病逆转)。在此,我们探讨了在T1D研究中共同构成识别预防和/或治愈该疾病方法的主要绊脚石的问题。我们从讨论人类T1D胰腺研究产生的新见解开始这一观点阐述;这些发现至少可以部分解释为什么以前寻求疾病预防/逆转的干预措施带来的益处不足。然后,我们转向可以优化未来临床试验结果的建议。最后,我们将注意力转向对全球T1D研究界的建议;我们认为这些信息有可能提高我们找到难以捉摸的T1D“治愈方法”的机会。

相似文献

1
Factors impeding the discovery of an intervention-based treatment for type 1 diabetes.阻碍发现1型糖尿病基于干预的治疗方法的因素。
Clin Exp Immunol. 2016 Jan;183(1):1-7. doi: 10.1111/cei.12656. Epub 2015 Jul 24.
2
Diabetes technology and treatments in the paediatric age group.儿科年龄组的糖尿病技术与治疗
Int J Clin Pract Suppl. 2011 Feb(170):76-82. doi: 10.1111/j.1742-1241.2010.02582.x.
3
Pediatric Type 1 Diabetes: Mechanisms and Impact of Technologies on Comorbidities and Life Expectancy.儿科 1 型糖尿病:技术对合并症和预期寿命的影响及其作用机制。
Int J Mol Sci. 2023 Jul 26;24(15):11980. doi: 10.3390/ijms241511980.
4
Beyond HbA1c.超越糖化血红蛋白。
J Diabetes. 2017 Dec;9(12):1052-1053. doi: 10.1111/1753-0407.12590. Epub 2017 Sep 13.
5
Insulin during pregnancy, labour and delivery.妊娠、分娩和产程中的胰岛素。
Best Pract Res Clin Obstet Gynaecol. 2011 Feb;25(1):65-76. doi: 10.1016/j.bpobgyn.2010.10.002. Epub 2010 Dec 24.
6
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.1型糖尿病强化血糖控制与传统血糖控制的比较
Cochrane Database Syst Rev. 2014 Feb 14;2014(2):CD009122. doi: 10.1002/14651858.CD009122.pub2.
7
Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.1 型糖尿病诊断时采用连续皮下胰岛素输注与多次皮下注射胰岛素治疗儿童和青少年:SCIPI RCT。
Health Technol Assess. 2018 Aug;22(42):1-112. doi: 10.3310/hta22420.
8
TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial.TNF-α 抑制剂治疗 1 型糖尿病:探索关键临床试验之路。
Front Immunol. 2024 Oct 1;15:1470677. doi: 10.3389/fimmu.2024.1470677. eCollection 2024.
9
A cognitive behavioral therapy intervention to reduce fear of hypoglycemia in young adults with type 1 diabetes (FREE): study protocol for a randomized controlled trial.一项认知行为疗法干预措施,以减少 1 型糖尿病年轻患者对低血糖的恐惧(FREE):一项随机对照试验的研究方案。
Trials. 2019 Dec 30;20(1):796. doi: 10.1186/s13063-019-3876-4.
10
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.2016-2018 年 T1D 交换计划中 1 型糖尿病管理状况和结果。
Diabetes Technol Ther. 2019 Feb;21(2):66-72. doi: 10.1089/dia.2018.0384. Epub 2019 Jan 18.

引用本文的文献

1
DGCR2 targeting affibody molecules for delivery of drugs and imaging reagents to human beta cells.用于将药物和成像试剂递送至人β细胞的靶向DGCR2的亲和体分子。
Sci Rep. 2025 Jan 2;15(1):417. doi: 10.1038/s41598-024-84574-y.
2
Metabolic control, adherence to the gluten-free diet and quality of life among patients with type 1 diabetes and celiac disease.1型糖尿病合并乳糜泻患者的代谢控制、坚持无麸质饮食及生活质量
Diabetol Metab Syndr. 2023 Sep 28;15(1):189. doi: 10.1186/s13098-023-01167-x.
3
NK Cell Subsets Changes in Partial Remission and Early Stages of Pediatric Type 1 Diabetes.NK 细胞亚群在儿童 1 型糖尿病部分缓解期和早期的变化。
Front Immunol. 2021 Jan 25;11:611522. doi: 10.3389/fimmu.2020.611522. eCollection 2020.
4
A mutant α1antitrypsin in complex with heat shock proteins as the primary antigen in type 1 diabetes in silico investigation.1 型糖尿病中与热休克蛋白形成复合物的突变型α1 抗胰蛋白酶作为主要抗原的计算机模拟研究。
Sci Rep. 2021 Feb 4;11(1):3002. doi: 10.1038/s41598-021-82730-2.
5
Immunomodulatory Dual-Sized Microparticle System Conditions Human Antigen Presenting Cells Into a Tolerogenic Phenotype and Inhibits Type 1 Diabetes-Specific Autoreactive T Cell Responses.免疫调节双粒径微粒系统将人类抗原呈递细胞诱导为耐受表型,并抑制 1 型糖尿病特异性自身反应性 T 细胞反应。
Front Immunol. 2020 Oct 22;11:574447. doi: 10.3389/fimmu.2020.574447. eCollection 2020.
6
Why Don't We Have a Vaccine Against Autoimmune Diseases? - A Review.为什么我们没有针对自身免疫性疾病的疫苗?——综述
J Clin Cell Immunol. 2019;10(1). doi: 10.4172/2155-9899.1000574. Epub 2019 Jan 31.
7
Mobile health in the management of type 1 diabetes: a systematic review and meta-analysis.移动健康在1型糖尿病管理中的应用:一项系统评价与荟萃分析
BMC Endocr Disord. 2019 Feb 13;19(1):21. doi: 10.1186/s12902-019-0347-6.
8
Alpha-1 Antitrypsin Therapy for Autoimmune Disorders.α-1抗胰蛋白酶治疗自身免疫性疾病
Chronic Obstr Pulm Dis. 2018 Oct 5;5(4):289-301. doi: 10.15326/jcopdf.5.4.2018.0131.
9
Relative Pancreas Volume Is Reduced in First-Degree Relatives of Patients With Type 1 Diabetes.1 型糖尿病患者一级亲属的胰腺相对体积减小。
Diabetes Care. 2019 Feb;42(2):281-287. doi: 10.2337/dc18-1512. Epub 2018 Dec 14.
10
Skin-Related Complications Among Adolescents With Type 1 Diabetes Using Insulin Pump Therapy.使用胰岛素泵治疗的1型糖尿病青少年的皮肤相关并发症
Clin Med Insights Endocrinol Diabetes. 2018 Sep 5;11:1179551418798794. doi: 10.1177/1179551418798794. eCollection 2018.

本文引用的文献

1
The streetlight effect in type 1 diabetes.1型糖尿病中的路灯效应。
Diabetes. 2015 Apr;64(4):1081-90. doi: 10.2337/db14-1208.
2
Function of Isolated Pancreatic Islets From Patients at Onset of Type 1 Diabetes: Insulin Secretion Can Be Restored After Some Days in a Nondiabetogenic Environment In Vitro: Results From the DiViD Study.1型糖尿病发病初期患者分离胰岛的功能:在体外非致糖尿病环境中培养数天后胰岛素分泌可恢复:DiViD研究结果
Diabetes. 2015 Jul;64(7):2506-12. doi: 10.2337/db14-1911. Epub 2015 Feb 12.
3
Expression of human leukocyte antigen class I in endocrine and exocrine pancreatic tissue at onset of type 1 diabetes.1型糖尿病发病时人类白细胞抗原I类分子在内分泌和外分泌胰腺组织中的表达
Am J Pathol. 2015 Jan;185(1):129-38. doi: 10.1016/j.ajpath.2014.09.004.
4
Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.抗胸腺细胞球蛋白/粒细胞集落刺激因子治疗可保留已确诊1型糖尿病患者的β细胞功能。
J Clin Invest. 2015 Jan;125(1):448-55. doi: 10.1172/JCI78492. Epub 2014 Dec 15.
5
Immune therapy for treating type 1 diabetes: challenging existing paradigms.用于治疗1型糖尿病的免疫疗法:挑战现有范式。
J Clin Invest. 2015 Jan;125(1):94-6. doi: 10.1172/JCI79190. Epub 2014 Dec 15.
6
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?美国食品药品监督管理局近期就免疫抑制药物和抗癌药物引发的乙型肝炎再激活发出警告:这只是冰山一角吗?
Hepatology. 2015 Feb;61(2):703-11. doi: 10.1002/hep.27609.
7
Losing a grip on the notion of β-cell specificity for immune responses in type 1 diabetes: can we handle the truth?对1型糖尿病免疫反应中β细胞特异性概念的把握失准:我们能面对真相吗?
Diabetes. 2014 Nov;63(11):3572-4. doi: 10.2337/db14-1069.
8
Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes.外分泌胰腺中免疫细胞浸润增加:对1型糖尿病发病机制的可能作用。
Diabetes. 2014 Nov;63(11):3880-90. doi: 10.2337/db14-0549. Epub 2014 Jun 19.
9
Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes.血液和胰岛表型表明1型糖尿病存在免疫异质性。
Diabetes. 2014 Nov;63(11):3835-45. doi: 10.2337/db14-0365. Epub 2014 Jun 17.
10
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.Alefacept 靶向治疗新发 1 型糖尿病(T1DAL 研究):一项随机、双盲、安慰剂对照的 2 期临床试验的 12 个月结果。
Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.